CA-CALDERA-MEDICAL
27.6.2024 15:01:29 CEST | Business Wire | Press release
Caldera Medical, a global leader in women’s pelvic health, is proud to announce its sponsorship of the Cynisca Cycling team. This partnership reflects Caldera Medical’s unwavering commitment to advancing women’s health and empowerment through sports and community engagement.
Cynisca Cycling, an elite women's professional cycling team, is dedicated to elevating female athletes and promoting gender equality in sports. The collaboration with Caldera Medical, renowned for its humanitarian efforts in women's health, is poised to drive significant impact in both the sporting and healthcare arenas.
“We’re extremely pleased to share this new development between our team and Caldera Medical,” commented Robin Farina, Cynisca operations and performance director. “Just like Cynisca, Caldera has made a commitment to advancing women. Through our collaboration, we’ll continue to support women both on and off the bike.”
“Our sponsorship of Cynisca Cycling aligns perfectly with Caldera Medical’s mission to enhance the quality of life for women around the world,” said Bryon Merade, CEO of Caldera Medical. “We believe that empowering women in sports contributes to their overall well-being and health. By supporting Cynisca Cycling, we aim to underscore the importance of physical activity, resilience, and community for women's health.”
Caldera Medical’s involvement with Cynisca Cycling will include:
Health and Wellness Workshops: Organizing workshops focused on pelvic health, mental wellness, and overall physical health for the athletes and their communities.
Awareness Campaigns: Launching joint campaigns to educate the public about women's health issues and the importance of regular check-ups and active lifestyles.
Community Engagement: Participating in community events and activities that promote women's health and empowerment.
This sponsorship represents a significant step in Caldera Medical’s broader mission to address and improve women's health globally. The partnership with Cynisca Cycling will provide a dynamic platform to promote health, fitness, and empowerment among women, resonating with Caldera’s core values of compassion, excellence, and innovation.
About Caldera Medical
Caldera Medical is a medical device company solely focused on women’s health with a commitment to our mission of “Improving the Quality of Life for Women!” Caldera Medical develops, manufactures and markets best-in-class surgical products for the treatment of Stress Urinary Incontinence, Pelvic Organ Prolapse Polyps and Fibroids.
Caldera Medical forms close relationships with surgeons and continues to build the company around a principle of customer intimacy. In partnership with its surgeon customers, Caldera Medical has the largest humanitarian program of any women’s health company. It is committed to treating one million women in underserved populations around the world by the year 2027.
About Cynisca Cycling
Cynisca Cycling is a UCI-registered Women’s Continental Team (CYN-USA), dedicated to providing inspiration and support for women to reach the highest levels in cycling - both on and off the bike. The team provides professional support and guidance around a select racing program at the top European and U.S. events.
Launched in 2022 in partnership with USA Cycling, the team began racing in 2023 with an international roster now featuring twelve select North American riders who hold three national titles and a Pan American championship title. Other countries represented include France, Ireland, and Canada. Cynisca is committed to fair pay for female athletes and to providing employment opportunities for women.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627021263/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting udvider sin teknologiplatform i Frankrig20.3.2026 17:28:00 CET | Pressemeddelelse
Andersen Consulting udvider sit udbud inden for digital transformation med en samarbejdsaftale med Teolia Consulting, et fransk firma, der specialiserer sig i projekt- og produktstyring, cloud-platformsudvikling, datatransformation samt implementering og brug af Atlassian-pakken. Teolia Consulting blev grundlagt i 2014 og hjælper organisationer med at opnå digital performance, fra agile metoder til løsninger, der reducerer lanceringstiden. Virksomhedens ekspertise består i at levere integrerede strategier, der bringer teknologi og organisatorisk forandring i overensstemmelse. Virksomheden arbejder på tværs af brancher, herunder inden for bank- og finanssektoren, forsikring, mode og detailhandel, og hjælper kunder med at få større robusthed og accelerere deres digitale modenhed. "Hos Teolia Consulting mener vi, at ægte transformation opstår, når teknologi og mennesker udvikler sig sammen," sagde Lucienne Jacquet, der er administrerende partner i Teolia. "Ved at samarbejde med Andersen C
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 15:00:00 CET | Press release
- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentation
MUSASHI JAPAN by TAIMATSU Launches “Road to Shogun” – A Journey Through Craftsmanship and Discovery20.3.2026 13:58:00 CET | Press release
Musashi Japan by TAIMATSU Co., Ltd., a contemporary Japanese knife brand rooted in the spirit of craftsmanship and cultural harmony, has announced its newest experiential campaign: “Road to Shogun.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320887471/en/ Designed as the brand’s most ambitious customer journey to date, the campaign invites visitors to explore participating Musashi Japan stores while discovering the traditions, culture and craftsmanship that inspire the brand. Inspired by the journey towards mastery, the experience encourages participants to progress through a series of ranks whilst visiting stores and unlocking rewards that celebrate elements of everyday Japanese culture. At Musashi Japan, craftsmanship is not only about the final product, but also about the path taken to achieve mastery. The Road to Shogun reflects this philosophy by guiding customers through a journey that mirrors the dedication, cu
Futur Delivers Strong Growth and Record Profit in 202520.3.2026 12:05:00 CET | Press release
In 2025, Futur added 21,000 new customers and the inflows amounted to 34 billion kronor. At the end of the year, the total savings capital was 252 billion kronor, an increase of 7% from the previous year and a new record level. "2025 was a record year for Futur. In a market characterized by sharp market fluctuations, Futur continued to invest, grow and deliver strong results. Behind this record performance is stable customer growth, strong inflows and cost discipline. Our close cooperation with over 60 partners gives customers the freedom to choose the asset management and advisory services that best suit them. The strategy of letting the customer choose is appreciated, which is reflected in us welcoming more than 21,000 new customers during the year", says Torgny Johansson, CEO of Futur. "We are optimistic about the future. Futur has great opportunities to continue growing in the coming years by developing innovative and efficient services for savings and pensions. I am proud of how a
Lyten to Establish a Lyten Industrial Hub in Poland20.3.2026 12:00:00 CET | Press release
Lyten announces the establishment of its next Lyten Industrial Hub in Gdańsk, Poland. The hub will bring together key manufacturing and digital resources to support energy infrastructure, the development of artificial intelligence, and the defense sector. In February 2026, Lyten announced the creation of the first Lyten Industrial Hub in Sweden, combining battery production operations there with a 1 GW AI data center campus. Lyten plans to complete its feasibility study by the end of 2026 to determine the full development plan Lyten, the supermaterial applications company and global leader in an energy storage, has announced its interest in establishing a Lyten Industrial Hub in Poland. In 2026, Lyten will conduct a feasibility study to assess manufacturing requirements for Lyten products, potential private and public partnerships, and the necessary energy and utility infrastructure. The industrial hub will be built around Lyten Dwa – the energy storage production plant and R&D center
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
